Abstract
BackgroundBreast cancer (BC) is the most frequent tumour in women. Triple negative tumours (TNBC)–which are associated with minor survival rates—lack markers predictive of response to anticancer drugs. Triple negative tumours frequently metastasise to the central nervous system (CNS).ObjectiveThe main objective of this study was to study differences in tumour protein expression between patients with CNS metastases and those without this kind of spread, and propose new biomarkers.MethodsA retrospective study was performed. Targeted proteomics and statistical analyses were used to identify possible biomarkers.ResultsProteins were quantified by a targeted proteomics approach and protein expression data were successfully obtained from 51 triple negative formalin-fixed paraffin-embedded samples. ISG15, THBS1 and AP1M1 were identified as possible biomarkers related with CNS metastasis development.ConclusionsThree possible biomarkers associated with CNS metastases in TNBC tumours were identified: ISG15, THBS1 and AP1M1. They may become markers predicting the appearance of CNS infiltration in triple negative BC.
Highlights
Triple-negative breast cancer (TNBC) subtype represents approximately 10%–20% of all cases of breast cancer (BC) in Caucasian women and is associated with poor prognosis in terms of distant relapse-free survival and overall survival (OS) [1,2,3]
ISG15, THBS1 and AP1M1 were identified as possible biomarkers related with central nervous system (CNS) metastasis development
Three possible biomarkers associated with CNS metastases in TNBC tumours were identified: ISG15, THBS1 and AP1M1
Summary
Triple-negative breast cancer (TNBC) subtype represents approximately 10%–20% of all cases of breast cancer (BC) in Caucasian women and is associated with poor prognosis in terms of distant relapse-free survival and overall survival (OS) [1,2,3]. We have previously analysed the expression of these three genes in formalin-fixed paraffin-embedded (FFPE) samples from patients with TNBC and central nervous system (CNS) involvement and did not find such a correlation [5]. Mass-spectrometry-based proteomics is beginning to develop and to mature through a blend of enhanced instrumentation, sample preparation strategies and computational investigation [6,7,8]. These advances permit the distinguishing proof of thousands of proteins from tissue compatible with clinical daily practice, which is pertinent for the investigation of complex ailments. Triple negative tumours frequently metastasise to the central nervous system (CNS)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
